Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Xingdi Hu"'
Autor:
Tiffany R. Bellomo, Yuxi Liu, Thomas C. Gilliland, Hannah Miksenas, Sara Haidermota, Megan Wong, Xingdi Hu, Joaquim Rosado Cristino, Auris Browne, Jorge Plutzky, Sotirios Tsimikas, James L. Januzzi, Jr., Pradeep Natarajan
Publikováno v:
Journal of Lipid Research, Vol 65, Iss 7, Pp 100585- (2024)
The roles of lipoprotein(a) [Lp(a)] and related oxidized phospholipids (OxPLs) in the development and progression of coronary disease is known, but their influence on extracoronary vascular disease is not well-established. We sought to evaluate assoc
Externí odkaz:
https://doaj.org/article/656f0ededc1c4728a7450433adac033e
Autor:
James L. Januzzi, Roland R. J. van Kimmenade, Yuxi Liu, Xingdi Hu, Auris Browne, Jorge Plutzky, Sotirios Tsimikas, Ron Blankstein, Pradeep Natarajan
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 12 (2024)
Background Higher lipoprotein(a) and oxidized phospholipid concentrations are associated with increased risk for coronary artery disease and valvular heart disease. The role of lipoprotein(a) or oxidized phospholipid as a risk factor for incident hea
Externí odkaz:
https://doaj.org/article/c929cc04d11a40d19183551f02d71323
Autor:
Xingdi Hu, Joaquim Cristino, Raju Gautam, Rina Mehta, Diana Amari, Ji Haeng Heo, Siwei Wang, Nathan D. Wong
Publikováno v:
American Journal of Preventive Cardiology, Vol 14, Iss , Pp 100476- (2023)
Objective: Elevated lipoprotein(a) [Lp(a)] is a risk factor for atherosclerotic cardiovascular disease (ASCVD) and has no approved pharmacotherapies. Limited real-world data exists on the proportion of patients with available Lp(a) test results, char
Externí odkaz:
https://doaj.org/article/bfb688853a0b4578855ba4fea2f2328b
Autor:
Panagiotis Orfanos, Ana Filipa Fonseca, Xingdi Hu, Raju Gautam, Glenn Montgomery, Rachel Studer, Japinder Kaur, Nehul Saxena, Nitin Kaushik
Publikováno v:
PLoS ONE, Vol 18, Iss 11 (2023)
Externí odkaz:
https://doaj.org/article/ee8217f695db4300a40f301982927af9
Publikováno v:
Health Economics Review, Vol 9, Iss 1, Pp 1-13 (2019)
Abstract Background L-asparaginase is a key component of treatment for patients with acute lymphoblastic leukaemia (ALL) in the UK. Commonly used forms of asparaginase are native E. coli-derived asparaginase (native asparaginase) and pegaspargase in
Externí odkaz:
https://doaj.org/article/49a302c996184a7abd97664372c293e2
Autor:
Januzzi Jr, James L., van Kimmenade, Roland R. J., Yuxi Liu, Xingdi Hu, Browne, Auris, Plutzky, Jorge, Tsimikas, Sotirios, Blankstein, Ron, Natarajan, Pradeep
Publikováno v:
Journal of the American Heart Association; 6/18/2024, Vol. 13 Issue 12, p1-11, 11p
Autor:
Thomas C. Gilliland, Yuxi Liu, Reza Mohebi, Hannah Miksenas, Sara Haidermota, Megan Wong, Xingdi Hu, Joaquim Rosado Cristino, Auris Browne, Jorge Plutzky, Sotirios Tsimikas, James L. Januzzi, Pradeep Natarajan
Publikováno v:
Journal of the American College of Cardiology. 81:1780-1792
Autor:
Sushil Allen Luis, Martin M. LeWinter, Matthew Magestro, Maral DerSarkissian, Mei Sheng Duh, Rose Chang, Kalé Kponee-Shovein, Aruna Muthukumar, Xingdi Hu, Michelle Z. Lim-Watson, Allan L. Klein
Publikováno v:
Current Medical Research and Opinion. 38:1385-1389
To obtain a nationally representative annualized estimate of the prevalence of pericarditis (inflammation of the pericardium) in the United States (US) in order to better understand the potential burden on the health care system. Three nationally rep
Autor:
Patrick A Flume, Reta Fischer Biner, Damian G Downey, Cynthia Brown, Manu Jain, Rainald Fischer, Kris De Boeck, Gregory S Sawicki, Philip Chang, Hildegarde Paz-Diaz, Jaime L Rubin, Yoojung Yang, Xingdi Hu, David J Pasta, Stefanie J Millar, Daniel Campbell, Xin Wang, Neil Ahluwalia, Caroline A Owen, Claire E Wainwright, Ronald L. Gibson, Steven M. Rowe, Noah Lechtzin, Richard C. Ahrens, Karen S. McCoy, Moira Aitken, Scott H. Donaldson, Kimberly Ann McBennett, Joseph M. Pilewski, Joanne Billings, Carlos Milla, Ronald Rubenstein, Daniel Brian Rosenbluth, Rachel Linnemann, Michael R. Powers, Christopher Fortner, Carla Anne Frederick, Theodore G. Liou, Philip Black, Janice Wang, John L. Colombo, Maria Berdella, Maria Veronica Indihar, Cynthia D. Brown, Michael Anstead, Lara Bilodeau, Leonard Sicilian, James Jerome Tolle, Kathryn Moffett, Samya Nasr, Jennifer Taylor-Cousar, Tara Lynn Barto, Nicholas Antos, John S. Rogers, Bryon Quick, Henry R. Thompson, Gregory Sawicki, Bruce Barnett, Robert L. Zanni, Thomas C. Smith, Karen D. Schultz, Claire Keating, Patrick Flume, Gregory J. Omlor, Alix Ashare, Karen Voter, Nighat Mehdi, Maria Gabriela Tupayachi Ortiz, Tonia E. Gardner, Steven R. Boas, Barbara Messore, Edith Zemanick, Raksha Jain, Michael McCarthy, Dana G. Kissner, Kapilkumar Patel, John McNamara, Julie Philley, Ariel Berlinski, Francisco J. Calimano, Terry Chin, Douglas Conrad, Cori Daines, Hengameh H. Raissy, Thomas G. Keens, Jorge E. Lascano, Bennie McWilliams, Brian Morrissey, Santiago Reyes, Subramanyam Chittivelu, Sabiha Hussain, Arvey Stone, James Wallace, Ross Klingsberg, Julie A. Biller, Stephanie Bui, Olaf Sommerburg, Elisabetta Bignamini, Mirella Collura, Alexander Moller, Donatello Salvatore, Chantal Belleguic, Lea Bentur, Ori Efrati, Eitan Kerem, Dario Prais, Esther Quintana Gallego, Peter Barry, Galit Livnat-Levanon, Jose Ramon Villa Asensi, David Stuart Armstrong, Oscar Asensio de la Cruz, Francis Gilchrist, Diana Elizabeth Tullis, Bradley Quon, Larry C. Lands, Nancy Morrison, Annick Lavoie, Barry Linnane, Okan Elidemir, Felix Ringshausen, Matthias Kappler, Helge Hebestreit, Jochen Mainz, Alexander Kiefer, Cordula Koerner-Rettberg, Doris Staab, Wolfgang Gleiber, Tacjana Pressler, Florian Stehling, Andreas Hector, Sivagurunathan Sutharsan, Lutz Naehrlich, Damian Downey, Jane Carolyn Davies, Robert Ian Ketchell, Mary Patricia Carroll, Simon Doe, Gordon MacGregor, Edward Fairbairn Nash, Nicholas Withers, Daniel Gavin Peckham, Martin James Ledson, Sonal Kansra, Timothy William Rayner Lee, Bertrand Delaisi, Gilles Rault, Jean Le Bihan, Dominique Hubert, Isabelle Fajac, Isabelle Sermet-Gaudelus, Marleen Bakker, Bert Arets, Christiane De Boeck, Raphael Chiron, Philippe Reix, Catherine Mainguy, Eva van Braeckel, Anne Malfroot, Isabelle Durieu, Nadine Desmazes Dufeu, Anne Prevotat, Renske van der Meer, Petrus Merkus, E.J.M. Weersink, Isabel Barrio Gomez-Aguero, Silvia Gartner, Amparo Sole Jover, Antonio Alvarez Fernandez, Desmond William Cox, Edward F. McKone, Barry James Plant, Hiranjan Selvadurai, Simon David Bowler, Claire Elizabeth Wainwright, Daniel Smith, Peter Gordon Middleton, John William Wilson, Sonia Volpi, Carla Colombo, Benedetta Fabrizzi, Vincenzina Lucidi, Federico Cresta, Salvatore Cucchiara, Ernst Eber, Helmut Ellemunter, Isidor Huttegger, Lena Hjelte, Christina Krantz, Marita Gilljam
Publikováno v:
lancet. Respiratory medicine, 9(7), 733-746. Elsevier Limited
VX14-661-110 study group 2021, ' Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study ', The Lancet Respiratory Medicine . https://doi.org/10.1016/S2213-2600(20)30510-5
VX14-661-110 study group 2021, ' Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study ', The Lancet Respiratory Medicine . https://doi.org/10.1016/S2213-2600(20)30510-5
Summary Background Tezacaftor–ivacaftor is an approved cystic fibrosis transmembrane conductance regulator (CFTR) modulator shown to be efficacious and generally safe and well tolerated over 8–24 weeks in phase 3 clinical studies in participants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf49af3de3f90b3a65bf102dbba3756b
https://pure.amc.nl/en/publications/longterm-safety-and-efficacy-of-tezacaftorivacaftor-in-individuals-with-cystic-fibrosis-aged-12-years-or-older-who-are-homozygous-or-heterozygous-for-phe508del-cftr-extend-an-openlabel-extension-study(cc1b629c-44f6-4a77-aff2-ea80f4598819).html
https://pure.amc.nl/en/publications/longterm-safety-and-efficacy-of-tezacaftorivacaftor-in-individuals-with-cystic-fibrosis-aged-12-years-or-older-who-are-homozygous-or-heterozygous-for-phe508del-cftr-extend-an-openlabel-extension-study(cc1b629c-44f6-4a77-aff2-ea80f4598819).html
Publikováno v:
Health Economics Review
Health Economics Review, Vol 9, Iss 1, Pp 1-13 (2019)
Hu, X, Wildman, K P, Basu, S, Lin, P L, Rowntree, C & Saha, V 2019, ' The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia : A UK-based cost-utility analysis ', Health Economics Review, vol. 9, no. 1, 40 . https://doi.org/10.1186/s13561-019-0257-3
Health Economics Review, Vol 9, Iss 1, Pp 1-13 (2019)
Hu, X, Wildman, K P, Basu, S, Lin, P L, Rowntree, C & Saha, V 2019, ' The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia : A UK-based cost-utility analysis ', Health Economics Review, vol. 9, no. 1, 40 . https://doi.org/10.1186/s13561-019-0257-3
Background L-asparaginase is a key component of treatment for patients with acute lymphoblastic leukaemia (ALL) in the UK. Commonly used forms of asparaginase are native E. coli-derived asparaginase (native asparaginase) and pegaspargase in first-lin